HimmelfarbJ., StenvinkelP., IkizlerT.A., HakimR.M.The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia.Kidney Int2002; 62: 1524–38.
4.
StenvinkelP., LindholmB., HeimbürgerO.Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease.Semin Dial2004; 17: 505–15.
5.
KumarS., RafteryM., YaqoobM., FanS.L.S.Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in peritoneal dialysis patients.Perit Dial Int2007; 27: 283–7.
6.
RidkerP.M.Clinical application of C-reactive protein for cardiovascular disease detection and prevention.Circulation2003; 107: 363–9.
7.
NohH., LeeS.W., KangS.W., ShinS.K., ChoiK.H., LeeH.Y.Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients.Nephrol Dial Transplant1998; 18: 387–94.
8.
DuclouxD., Bresson-VautrinC., KribsM., AbdelfatahA., ChalopinJ-MC-reactive protein and cardiovascular disease in peritoneal dialysis patients.Kidney Int2002; 62: 1417–22.
9.
WangA.Y., WooJ., LamC.W., WangM., SeaM.M., LuiS.F.Is a single time-point C-reactive protein predictive of outcome in peritoneal dialysis patients?J Am Soc Nephrol2003; 14: 1871–9.
10.
RossR.Atherosclerosis: an inflammatory disease.N Engl J Med1999; 340: 115–26.
11.
StenvinkelP.C-reactive protein—does it promote vascular disease?Nephrol Dial Transplant2006; 21: 2718–20.
12.
StenvinkelP., KettelerM., JohnsonR.J., LindholmB., Pecoits FilhoR., RiellaM.IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly.Kidney Int2005; 67: 1216–33.
13.
CasasJ.P., ShahT., CooperJ., HaweE., McMahonA.D., GaffneyD.Insight into the nature of the CRP-coronary event association using Mendelian randomization.Int J Epidemiol2006; 35: 922–31.
14.
ZhangL., KaoL., Berthier-SchaadY., PlantingaL., FinkN., SmithM.W.C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort.Am J Kidney Dis2007; 49: 118–26.
15.
JialalI., SteinD., BalisD., GrundyS.M., Adams-HuetB., DevarajS.Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels.Circulation2001; 103: 1933–5.
16.
AlbertM.A., DanielssonE., RifaiN., RidkerPM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study.JAMA2001; 286: 64–70.
17.
RidkerP.M., CannonC.P., MorrowD., RifaiN., RoseL.M., McCabeC.H.C-reactive protein levels and outcome after statin therapy.N Engl J Med2005; 352: 20–8.
MärzW., WinklerK., NauckM., BöhmB.O., WinkelmannB.R.Effects of statins on C-reactive protein and interleukin-6 (The Ludwigshafen Risk and Cardiovascular Health Study).Am J Cardiol2003; 92: 305–8.
20.
ChangJ.W., YangW.S., MinW.K., LeeS.K., ParkJ.S., KimS.B.Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.Am J Kidney Dis2002; 39: 1213–17.
21.
VernaglioneL., CristofanoC., MuscogiuriP., ChimientiS.Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?Am J Kidney Dis2004; 43: 471–8.
22.
IchiharaA., HayashiM., RyuzakiM., HandaM., FurukawaT., SarutaT.Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.Nephrol Dial Transplant2002; 17: 1513–17.
23.
IkejiriA., HiranoT., MuryamaS., YoshinoG., GushikenN., HyodoT.Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.Metabolism2004; 53: 1113–17.
24.
MalyszkoJ., MalyszkoJ.S., HryszkoT., MysliwiecM.Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients.Blood Coagul Fibrinolysis2004; 15: 463–7.
25.
van der AkkerJ.M., BredieS.J., DiepenveenS.H., van TitsL.J., StalenhoefA.F., van LeusenR.Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.J Nephrol2003; 16: 238–44.
26.
TsirpanlisG., BoufidouF., ManganasS., ChantzisK., BletaA., StamatelouK.Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients.Blood Purif2004; 22: 518–24.
27.
MasonN.A., BailieG.R., SatayathumS., Bragg-GreshamJ.L., AkibaT., AkizawaT.HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients.Am J Kidney Dis2005; 45: 119–26.
28.
TonelliM., SacksF.M., KiberdB., CurhanG.C.Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.Ann Intern Med2003; 138: 98–104.
29.
TonelliM., IslesC., CurhanG.C., TonkinA., PfefferM.A., ShepherdJ.Effect of pravastatin on cardiovascular events in people with chronic kidney disease.Circulation2004; 110: 1557–63.
30.
WannerC., KraneV., MarzW., OlschewskiM., MannJ.F., RufG.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.N Engl J Med2005; 353: 238–48.
